Memantine Hydrochloride Tablet
Product Images NDC 63629-2511

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 63629-2511). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure of Memantine Hydrochloride showing its molecular framework with labeled functional groups including NH2 and HCl.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph depicting mean changes from baseline in ADCS-ADL scores over 28 weeks of treatment, comparing Memantine Hydrochloride (M.HCl) and placebo groups. The vertical axis shows mean change with standard error bars, while the horizontal axis represents weeks of treatment. Lines illustrate clinical improvement and decline trends for each group.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A cumulative percentage curve comparing patients on Memantine Hydrochloride (M.HCl) versus placebo, plotted against the ADCS-ADL change from baseline. The graph shows the cumulative percentage of patients on the vertical axis and the ADCS-ADL change from baseline on the horizontal axis, with distinct lines for Memantine Hydrochloride and placebo groups.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

A line graph showing mean change from baseline in SIB score over 28 weeks of treatment comparing Memantine Hydrochloride (M.HCl) and placebo. The vertical axis measures mean change and the horizontal axis shows weeks of treatment. The plot indicates clinical improvement or decline trends for both groups over time.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A cumulative percentage graph showing patients on the y-axis and SIB change from baseline on the x-axis. Two groups are compared: one receiving Placebo and the other Memantine Hydrochloride (M. HCl). The lines indicate cumulative percentage trends for each group across different SIB change values.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

A line graph depicting the mean change from baseline in ADCS-ADL score over 24 weeks of treatment. Two treatment groups are shown: Placebo/Donepezil (black squares) and Memantine Hydrochloride/Donepezil (open circles). The y-axis measures mean change with error bars, indicating clinical improvement or decline. The x-axis represents weeks of treatment from 0 to 24.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A cumulative percentage of patients graph depicting the ADCS-ADL change from baseline. It compares two treatment groups: Placebo/Donepezil (solid squares) and Memantine Hydrochloride/Donepezil (open circles), showing patient distribution across various levels of change.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

A line graph showing the mean change from baseline in SIB (Severe Impairment Battery) score over 24 weeks of treatment. Two groups are compared: Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil. The vertical axis represents the mean change with error bars, while the horizontal axis represents weeks of treatment. Clinical improvement and decline are indicated on the graph.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

A cumulative percentage of patients chart showing SIB (Severe Impairment Battery) change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The chart compares placebo/donepezil (black squares) and Memantine Hydrochloride/donepezil (open circles) groups, illustrating their respective cumulative responses.*

FDA Label Image

Label (Lbl636292511)

Memantine Hydrochloride Tablets, USP 10 mg oral tablets label. The label shows the strength as 10 mg and states a quantity of 500 tablets. It is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and includes storage instructions and a warning to keep medication out of reach of children. The label also features a barcode and the BRP Pharmaceuticals logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.